National approval for MOB-015 in Sweden
STOCKHOLM, August 4[th], 2023, Moberg Pharma AB (OMX:MOB) hereby announces that MOB-015 has received national approval for the company’s home market, Sweden, for the treatment of mild to moderate fungal infections of the nails in adults. This is the second country to grant national approval for MOB-015, following the approval in Ireland announced July 31[st], and Sweden is the first country where MOB-015 has been approved for over-the-counter (OTC) use.Grant of market authorization in Sweden is significant as our commercialization rollout is planned to start in our home market. We will